GOSS vs. MCRB, PRQR, CAPR, SKYE, PRLD, GLSI, SCPH, IXHL, CRVO, and IVA
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Seres Therapeutics (MCRB), ProQR Therapeutics (PRQR), Capricor Therapeutics (CAPR), Skye Bioscience (SKYE), Prelude Therapeutics (PRLD), Greenwich LifeSciences (GLSI), scPharmaceuticals (SCPH), Incannex Healthcare (IXHL), CervoMed (CRVO), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
Seres Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500.
In the previous week, Gossamer Bio had 15 more articles in the media than Seres Therapeutics. MarketBeat recorded 32 mentions for Gossamer Bio and 17 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.41 beat Gossamer Bio's score of 0.22 indicating that Gossamer Bio is being referred to more favorably in the news media.
Seres Therapeutics received 380 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 65.16% of users gave Gossamer Bio an outperform vote.
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Gossamer Bio's return on equity of 0.00% beat Seres Therapeutics' return on equity.
Seres Therapeutics has higher revenue and earnings than Gossamer Bio. Seres Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 418.08%. Gossamer Bio has a consensus price target of $7.65, suggesting a potential upside of 962.50%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Seres Therapeutics.
Summary
Seres Therapeutics beats Gossamer Bio on 10 of the 16 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
